drugset / Trial / NCT00092547

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

NCT00092547

Phase 3 Completed 1781 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

This study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).

Timeline

Start
2003-10-08
Primary completion
2005-11-03
Completion
2015-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine 0.5 ml Intramuscular